Status:

UNKNOWN

Safety and Efficacy of Distal Embolic Protection Device in Vertebral Artery Origin Stenting

Lead Sponsor:

Xuanwu Hospital, Beijing

Conditions:

Adverse Event

Eligibility:

All Genders

40-80 years

Phase:

NA

Brief Summary

This is a prospective single-center,randomized controlled trial,aiming to investigate the safety and efficacy of distal EPD in vertebral artery origin stenting(VAOS);256 subjects will be recruited in ...

Detailed Description

Ischemic cerebrovascular diseases are associated with a high rate of mortality and disability rate, as a consequence, many related trials were conducted to perfect prophylaxis and treatment of ischemi...

Eligibility Criteria

Inclusion

  • Aged 40 to 80 years old;
  • VAO atherosclerotic stenosis results in posterior circulation ischemic symptom refractory to best medical treatment;
  • symptomatic VAO atherosclerotic stenosis\>70% evaluated by computed tomograph angiography(CTA) or Magnetic Resonance Angiography(MRA) or digital subtraction angiography(DSA);
  • the diameter of the normal segment of the artery beyond the stenosis \>3.5mm;
  • written informed consent.

Exclusion

  • VAO stenosis is combined with ipsilateral vertebrobasilar disease including severe cranial vertebral artery stenosis and severe basilar artery stenosis.
  • VAO is occluded;
  • Patients who will be underwent bilateral VAOS due to bilateral VAO stenosis including someone with bilateral VAO stenosis \>70% and the patient who need contralateral VAOS after stenting in unilateral VAO due to recurrent posterior circulation ischemia refractory to best medical treatment.
  • VAO stenosis caused by arteritis,artery dissection, aplasia, vasculopathy caused by radiotherapy etc, other than atherosclerosis;
  • stroke within 30 days or myocardial infarction within 6 months;
  • contraindication of anticoagulant and antiplatelet agents; allergy to iodinated contrast agent;
  • severe comorbid diseases and intolerant to procedure; patient unlikely to cooperate with the procedure or provide informed consent.
  • High risk of difficulty or failure in EPD advance and retrieval due to the tortuosity of the culprit vertebral artery origin.

Key Trial Info

Start Date :

May 20 2017

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

July 1 2020

Estimated Enrollment :

256 Patients enrolled

Trial Details

Trial ID

NCT03381534

Start Date

May 20 2017

End Date

July 1 2020

Last Update

December 27 2017

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

XuanWu hospital

Beijing, China